| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/25/2001 | EP1117687A2 Compositions and methods for wt1 specific immunotherapy |
| 07/25/2001 | EP1117683A2 Tb vaccine and diagnostic based on antigens from the m. tuberculosis cell |
| 07/25/2001 | EP1117682A1 Novel peptides |
| 07/25/2001 | EP1117680A2 Ncam binding compounds |
| 07/25/2001 | EP1117679A2 Tumor antigens and ctl clones isolated by a novel procedure |
| 07/25/2001 | EP1117677A1 Ligand presenting assembly (lpa), method of preparation and uses thereof |
| 07/25/2001 | EP1117675A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 07/25/2001 | EP1117673A1 Mammaglobin, a secreted mammary-specific breast cancer protein |
| 07/25/2001 | EP1117439A1 Methods for identification, diagnosis, and treatment of breast cancer |
| 07/25/2001 | EP1117438A1 Tie2 antagonist antibodies |
| 07/25/2001 | EP1117437A1 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke |
| 07/25/2001 | EP1117436A1 Neisseria spp polypeptide, nucleic acid sequence and uses thereof |
| 07/25/2001 | EP1117435A1 Mutant cholera holotoxin as an adjuvant |
| 07/25/2001 | EP1117434A2 Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine |
| 07/25/2001 | EP1117433A1 Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
| 07/25/2001 | EP1117432A1 Carbohydrate vaccines for viral diseases |
| 07/25/2001 | EP1117431A1 Control of acidosis |
| 07/25/2001 | EP1117430A1 Genes differentially expressed in cancer cells to design cancer vaccines |
| 07/25/2001 | EP1117429A1 Chemokine receptor peptide vaccines for treatment and prevention of diabetes |
| 07/25/2001 | EP1117421A2 Methods for therapeutic vaccination |
| 07/25/2001 | EP1117400A2 Antibiotic compositions for treatment of the eye, ear and nose |
| 07/25/2001 | EP1117381A1 Calcium phosphate delivery vehicle and adjuvant |
| 07/25/2001 | EP1117355A1 Targeted therapy to a biomedical device |
| 07/25/2001 | EP0722338B1 Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
| 07/25/2001 | EP0577605B1 G protein-coupled glutamate receptors |
| 07/25/2001 | CN1305589A Improved immunodiagnostic assays using reducing agents |
| 07/25/2001 | CN1305525A Phagocytic assay method |
| 07/25/2001 | CN1305498A Peptide composition as immunogen for treatment of allergy |
| 07/25/2001 | CN1305497A Monoclonal antibodies directed against the G3BP protein and use |
| 07/25/2001 | CN1305495A Peptide |
| 07/25/2001 | CN1305387A Enhancement of antibody-cytokine fusion protein medicated immune responses by co-administration with prostaglandin inhibitor |
| 07/25/2001 | CN1305386A Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 07/25/2001 | CN1305384A Immunomodulatory compositions of MMTV antigens and method of using same |
| 07/24/2001 | US6265567 Isolated FrpB nucleic acid molecule |
| 07/24/2001 | US6265563 Nucleotide sequences probes for use as diagnostic tools and drug screening |
| 07/24/2001 | US6265562 Nucleotide sequences coding transcription factor; for the treatment and prevention of infection, tumors, leukemias, autoimmune disease, allergies, arthritis, inflammation, organ rejection, graft versus host disease and coagulation defects |
| 07/24/2001 | US6265543 Polypeptide for the treatment of eye disorders, tumors, cancer, psoriasis, trauma, psychological, burns and ulcers |
| 07/24/2001 | US6265539 Prophylaxis and therapy of acquired immunodeficiency syndrome |
| 07/24/2001 | US6265200 HIV-3 retrovirus and its use |
| 07/24/2001 | US6265198 Parasite astacin metalloendopeptidase proteins |
| 07/24/2001 | US6265189 Expressing polypeptide in cell culture; insert gene into viral expression vector, transform cells, recover preferential polypeptide |
| 07/24/2001 | US6265188 Nucleotide sequence coding a enzymatic polypeptide; for use as a wound healing agent; for prevention of bacterial infection |
| 07/24/2001 | US6265184 Polynucleotides encoding chemokine receptor 88C |
| 07/24/2001 | US6265183 Direct molecular cloning of foreign genes into poxviruses and methods for the preparation of recombinant proteins |
| 07/24/2001 | US6265149 Screening sample for preferential immunological complexes; incubate sample with antigen, incubate sample with control, monitor complexes formed, count complexes in samples, more complexes in antigen sample indicates presence of retrovirus |
| 07/24/2001 | US6264995 Supercritical extraction with carbon dioxide |
| 07/24/2001 | US6264994 Compositions for treating alzheimer's disease and other amyloidoses |
| 07/24/2001 | US6264990 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity. |
| 07/24/2001 | US6264958 Polynucleotide |
| 07/24/2001 | US6264957 Product of infectious respiratory syncytial virus from cloned nucleotide sequences |
| 07/24/2001 | US6264955 Ferrichrome transport ATP-binding protein |
| 07/24/2001 | US6264954 Immunogenic peptide |
| 07/24/2001 | US6264953 Method of preparation and use for zona pellucida antigens and antibodies for sterilization and contraception |
| 07/24/2001 | US6264952 Method for protecting a mammalian host against infection by Brucella |
| 07/24/2001 | US6264948 Methods and compositions for inhibiting tumor cell growth |
| 07/24/2001 | US6264917 Targeted ultrasound contrast agents |
| 07/24/2001 | CA2065299C Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| 07/19/2001 | WO2001051635A2 Novel stra6 polypeptides |
| 07/19/2001 | WO2001051633A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 07/19/2001 | WO2001051619A2 Genetically modified fibroblast cell |
| 07/19/2001 | WO2001051617A1 Monocyte-derived dendritic cell subsets |
| 07/19/2001 | WO2001051608A2 Hybrid cells obtainable from antigen presenting cells |
| 07/19/2001 | WO2001051603A2 Pharmaceutical composition and method of using the same |
| 07/19/2001 | WO2001051523A2 Anti-angiogenic proteins and fragments and methods of use thereof |
| 07/19/2001 | WO2001051520A2 Nogo receptor-mediated blockade of axonal growth |
| 07/19/2001 | WO2001051517A2 Candida hemolysin - like proteins and their uses |
| 07/19/2001 | WO2001051516A2 Fusion proteins for stimulating cytotoxic t-cells |
| 07/19/2001 | WO2001051513A2 Ovarian tumor-associated sequences |
| 07/19/2001 | WO2001051512A2 Human and parasite orphan receptor proteins |
| 07/19/2001 | WO2001051083A2 Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| 07/19/2001 | WO2001051082A1 Composition of antigen and glycolipid adjuvant sublingual administration |
| 07/19/2001 | WO2001051081A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| 07/19/2001 | WO2001051080A2 Methods and compositions for obtaining disease protection for animals |
| 07/19/2001 | WO2001051074A1 Methods for treating pancreatic disorders |
| 07/19/2001 | WO2001051049A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 07/19/2001 | WO2001051008A2 Selective activation of a th1 or th2 lymphocyte regulated immune response |
| 07/19/2001 | WO2001005820A3 Method for down-regulating gdf-8 activity |
| 07/19/2001 | WO2001005418A3 Tissue regenerating agent |
| 07/19/2001 | WO2001004271A3 Respiratory syncytial viruses expressing immune modulatory molecules |
| 07/19/2001 | WO2000078800A3 Combined decorin binding protein and outer surface protein compositions and methods of use |
| 07/19/2001 | WO2000077043A3 Dna vaccines for pets and sport animals |
| 07/19/2001 | WO2000074716A3 Ige peptides for allergy immunotherapy |
| 07/19/2001 | WO2000041474A3 Anti-cd3 immunotoxins and therapeutic uses therefor |
| 07/19/2001 | WO2000040229A3 Synergistic tumorcidal response induced by histamine |
| 07/19/2001 | WO2000025808A9 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| 07/19/2001 | WO2000006198A3 Adjuvant comprising pulmonary surfactant |
| 07/19/2001 | US20010008934 Stablity; useful in drugs, vaccines, personal care/cosmetics, veterinary drugs/vaccines, foods, feeds, diagnostics, cleaning agents (detergents and decontaminants); catalytic and binding components of biosensors |
| 07/19/2001 | US20010008881 Method for the augmentation of gene expression |
| 07/19/2001 | US20010008759 Contacting target cells with member of antibody phage display library |
| 07/19/2001 | US20010008627 Controlling cell accumulation |
| 07/19/2001 | CA2823768A1 Hybrid cells |
| 07/19/2001 | CA2397741A1 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 07/19/2001 | CA2397396A1 Methods and compositions for obtaining disease protection for animals |
| 07/19/2001 | CA2397374A1 Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| 07/19/2001 | CA2397207A1 Novel stra6 polypeptides |
| 07/19/2001 | CA2397199A1 Nogo receptor-mediated blockade of axonal growth |
| 07/19/2001 | CA2397053A1 Human and parasite orphan receptor proteins |
| 07/19/2001 | CA2397030A1 Methods for treating pancreatic disorders |
| 07/19/2001 | CA2396996A1 Genetically modified fibroblast cell |
| 07/19/2001 | CA2396384A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |